Image

Specimens for Lung Cancer Panel Design

Specimens for Lung Cancer Panel Design

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This is an observational study designed to determine the optimal combination of biomarkers and clinical data for the early detection, confirmation, and better treatment of lung cancer including minimizing recurrence.

Description

Peripheral venous blood and clinical data will be collected from consented subjects with lung nodules identified in radiology that are suspicious for lung cancer before invasive diagnosis or treatment is initiated. Various analyses will be conducted to determine which subset of biomarkers is most likely to be the most useful in the clinic. Attributes considered are accuracy (sensitivity, specificity, improvement over other methods) and ease of collection and transport. Results will not be reported to treating physicians and will not alter care of the patient.

Eligibility

6.1 Criteria for the no prior cancer suspicious nodule arm

Inclusion
  1. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery.
  2. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months.
  3. Ability to understand the study and sign an informed consent form
  4. Relevant clinical data accessible
  5. Ability and willingness to safely donate 40 mL of blood
  6. Ability of the site to collect and process blood per protocol Exclusion

1\. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater.

2\. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary.

3\. Previous cancer diagnosis of any origin. 4. Is currently pregnant 5. Is currently a prisoner or becomes a prisoner at any point during the study 6. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf 6.2 Criteria for the previous cancer suspicious nodule arm

Inclusion

1\. The patient has at least one indeterminant nodule with a diameter greater than or equal to 5mm and a Mayo SPN risk greater than 5%, identified by radiology, that has not been biopsied or undergone surgery.

2\. The patient and the treating physician intend to follow up on the nodule with a biopsy procedure, PET scan, or active surveillance, with the procedure or next surveillance planned within the next 7 months.

3\. The patient has been in remission for a previous cancer not of lung origin for more than 5 years.

4\. Ability to understand the study and sign an informed consent form 5. Relevant clinical data accessible 6. Ability and willingness to safely donate 40 mL of blood 7. Ability of the site to collect and process blood per protocol Exclusion

  1. The patient has one or more nodules with a Mayo SPN risk over 50% or a diameter of 30mm or greater.
  2. The patient has received surgical prep, including antibiotics, anesthesia, etc. Fasting is not exclusionary.
  3. Previous cancer diagnosis in the lung (either of lung origin or metastasis to the lung).
  4. The treating physician believes the lung nodule is a recurrence of a previously diagnosed cancer.
  5. Is currently pregnant
  6. Is currently a prisoner or becomes a prisoner at any point during the study
  7. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf

6.3 Criteria for the healthy volunteer arm

Inclusion
  1. Ability to understand the study and sign an informed consent form
  2. Relevant clinical data accessible
  3. Ability and willingness to safely donate up to 40 mL of blood
  4. The ability of the site to collect and process blood per protocol Exclusion

1\. Is currently pregnant 2. Is currently a prisoner or becomes a prisoner at any point during the study 3. Is under age 18, is unable to consent, or requires a different person or entity to consent on their behalf

Study details
    Lung Nodules

NCT07401797

Maverix Medical

26 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.